ThermoGenesis's FDA-cleared pro-healing cell tech to hit US later this year
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for the Res-Q 60 system developed by stem cell specialist ThermoGenesis. The technology may now be used to prepare autologous platelet-rich plasma (PRP) from a patient's blood sample at the point of care. The PRP, a source of growth factors which has been shown to enhance healing, is mixed with autograft and/or allograft bone prior to application to a bone defect. The Rancho Cordova, California company says it hopes to form US distribution agreements "in the coming months", and begin selling Res-Q 60 later this year. The firm says that PRP is also potentially applicable to other conditions, including orthopaedic and cardiovascular indications.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.